Search research articles
Contact Us
Filters
Showing results (291-300 of 536) with videos related to
Page
of 54
Sort By:
Bone Marrow Transplantation
|
November 21, 2021
Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens
Janny M Yao, Dongyun Yang, Mary C Clark, et al.
Biorxiv : the Preprint Server for Biology
|
July 15, 2025
Longitudinal single cell RNA-sequencing reveals evolution of micro- and macro-states in chronic myeloid leukemia
David E Frankhouser, Dandan Zhao, Yu-Hsuan Fu, et al.
American Journal of Hematology
|
May 27, 2024
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia
Tamer Othman, Shanpeng Li, Jianying Zhang, et al.
Blood Cancer Journal
|
July 3, 2021
Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes
Ibrahim Aldoss, Raju Pillai, Dongyun Yang, et al.
The Journal of Clinical Investigation
|
March 3, 2011
NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human
Jianhua Yu, Takeki Mitsui, Min Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2007
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
William Blum, Rebecca B Klisovic, Bjoern Hackanson, et al.
Haematologica
|
June 12, 2013
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline
Jason H Mendler, Kati Maharry, Heiko Becker, et al.
Blood Advances
|
September 28, 2021
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study
Haris Ali, Ni-Chun Tsai, Timothy Synold, et al.
American Journal of Hematology
|
March 15, 2021
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)
Amandeep Salhotra, Ahmed Aribi, Dat Ngo, et al.
Blood
|
June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.
Page
of 54
Search research articles
Search
Showing results (291-300 of 536) with videos related to
Sort By:
Page
of 54
Bone Marrow Transplantation
|
November 21, 2021
Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens
Janny M Yao, Dongyun Yang, Mary C Clark, et al.
Biorxiv : the Preprint Server for Biology
|
July 15, 2025
Longitudinal single cell RNA-sequencing reveals evolution of micro- and macro-states in chronic myeloid leukemia
David E Frankhouser, Dandan Zhao, Yu-Hsuan Fu, et al.
American Journal of Hematology
|
May 27, 2024
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia
Tamer Othman, Shanpeng Li, Jianying Zhang, et al.
Blood Cancer Journal
|
July 3, 2021
Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes
Ibrahim Aldoss, Raju Pillai, Dongyun Yang, et al.
The Journal of Clinical Investigation
|
March 3, 2011
NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human
Jianhua Yu, Takeki Mitsui, Min Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2007
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
William Blum, Rebecca B Klisovic, Bjoern Hackanson, et al.
Haematologica
|
June 12, 2013
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline
Jason H Mendler, Kati Maharry, Heiko Becker, et al.
Blood Advances
|
September 28, 2021
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study
Haris Ali, Ni-Chun Tsai, Timothy Synold, et al.
American Journal of Hematology
|
March 15, 2021
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)
Amandeep Salhotra, Ahmed Aribi, Dat Ngo, et al.
Blood
|
June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.
Page
of 54